Relay Therapeutics Provides Update on RLY-2608 Progress
Relay Therapeutics Inc. has released promising interim results for its investigational drug RLY-2608 from the ReDiscover study. This ongoing clinical trial is designed to assess the safety and effectiveness of RLY-2608, both as a standalone treatment and in combination with fulvestrant, a widely used therapy for breast cancer. Additionally, the study explores exciting combinations with ribociclib, a CDK4 inhibitor created by Pfizer Inc.
Promising Results from Heavily Pretreated Patients
The interim data indicates that patients with PI3K?-mutated, HR+, HER2- locally advanced or metastatic breast cancer have shown significant clinical improvements. Despite having undergone extensive prior treatments, those who received RLY-2608 at a dosage of 600mg twice daily alongside fulvestrant experienced meaningful enhancements in progression-free survival (PFS).
Key Statistics from the Study
As of the data cut-off on August 12, several important statistics emerged from the cohort of 52 patients who qualified for the study:
Median Progression-Free Survival
The median PFS was recorded at 9.2 months across all observed mutations, increasing to 10.3 months specifically for patients with kinase mutations.
Clinical Benefit Rate
The clinical benefit rate (CBR) was noteworthy, standing at 57% for all patients, indicating a positive outcome for 20 out of 35 evaluable participants. CBR is generally defined as the percentage of patients who achieve a complete response, partial response, or stable disease for at least 24 weeks.
Response Rates and Patient Outcomes
Examining the response rates further, among the 30 patients evaluated for measurable disease, an impressive one-third achieved a partial response, resulting in an objective response rate (ORR) of 33%. Notably, nearly 75% of the patients experienced tumor reductions, with 73% demonstrating significant progress during treatment.
Insights on Patients with Kinase Mutations
A closer look at the 15 patients with kinase mutations revealed that over half, specifically 53%, achieved a partial response, with 8 patients confirming their response. This adds to the optimism surrounding the treatment's potential effectiveness.
Tolerability and Regulatory Pathway
Overall, RLY-2608 combined with fulvestrant showed favorable tolerability among the 118 patients treated thus far. Meanwhile, Relay Therapeutics is in discussions with the FDA about the regulatory pathway for another compound, lirafugratinib, and plans to submit a new drug application (NDA) while also targeting a supplemental NDA for FGFR2 fusions.
Future Plans and Financial Status
Looking forward, the company is focused on finding a commercial partner for lirafugratinib while continuing to develop its ongoing portfolio. By the end of the second quarter of 2024, Relay Therapeutics reported approximately $688 million in cash and cash equivalents, which is expected to support the company’s operations through the latter part of 2026.
Stock Performance and Market Response
In response to these developments, RLAY stock has experienced a significant increase, rising by 55.6% to $9.71 during the latest trading session. This surge reflects investor confidence in Relay Therapeutics' innovative treatment strategies and their potential impact on the market.
Frequently Asked Questions
What is RLY-2608?
RLY-2608 is an investigational drug developed by Relay Therapeutics that targets specific mutations in breast cancer.
What were the findings of the ReDiscover study?
The ReDiscover study showed clinically meaningful progression-free survival for patients treated with RLY-2608, particularly in those with specific mutations.
How well was RLY-2608 tolerated by patients?
RLY-2608 demonstrated favorable tolerability among the patients treated, suggesting a positive safety profile.
What is the company's future focus?
Relay Therapeutics is working to secure a commercial partnership for lirafugratinib while advancing its existing portfolio.
What financial position does Relay Therapeutics hold?
As of the second quarter of 2024, Relay Therapeutics had approximately $688 million in cash, which is anticipated to support operations until 2026.
